One of several considerations in medical decision making is value (12) . Cost-effectiveness analysis (CEA) is one approach to determining medication value by quantifying the benefits and costs of different treatment options. The basic conduct and interpretation of CEAs have been described previously (13) . With the goal of aiding decision making, we estimated the incremental costs and costeffectiveness of sacubitril-valsartan relative to ACEIs for the treatment of HFrEF. MODEL INPUTS. PARADIGM-HF. Cardiovascular mortality risk. The risk of cardiovascular mortality was derived from the results of the PARADIGM-HF trial (10) . During the trial follow-up, 13.3% of patients receiving sacubitril-valsartan, and 16.5% of patients receiving enalapril experienced cardiovascular mortality. In the base case, these were converted to 3-month probabilities, and the probability of dying of cardiovascular causes during each 3-month model cycle was 1.49% in the sacubitril-valsartan group and 1.87% in the enalapril group ( Table 1 ). An assumption of the model is that the cardiovascular mortality rate observed in PARADIGM-HF trial remained constant throughout the model time horizon.
HF hospitalization risk. The cumulative rate of HF hospitalizations was lower in the sacubitril-valsartan group than in the enalapril group in PARADIGM-HF (rate ratio: 0.77; 95% confidence interval: 0.67 to 0.89) (15) . Careful graphical measurement of the cumulative number of hospitalizations for HF in Heart Failure) (17) (18) (19) . We made the conservative assumption that the probability of disease progression between the health states was the same for both treatment groups, because it is unclear how sacubitril-valsartan alters NYHA progression relative to enalapril. We also assumed that transition probabilities were fixed over time. Values are %. All inputs are based on a 3-month cycle length.
CV ¼ cardiovascular; HF ¼ heart failure; NYHA ¼ New York Heart Association. Abbreviations as in Table 1 .
valsartan ( Table 3 The model was said to be sensitive to variables that qualitatively changed the results from the base case.
In addition to varying model inputs, we also varied model duration from 3 years (median follow-up in PARADIGM-HF was 27 months) to a lifetime.
We conducted a PSA allowing all variables to simultaneously vary stochastically. A second-order Monte Carlo simulation was performed (n ¼ 10,000) based on the variable specific distributions. Results of the PSA are presented graphically as scatterplots and cost-effectiveness acceptability curves.
RESULTS
BASE CASE. The discounted costs, benefits, and cost-effectiveness of the 2 treatment strategies over a 40-year time horizon, which was considered a lifetime perspective, are presented in Table 5 . Per QALY gained .
50,959
All costs (in U.S. dollars), life years, and QALYs were discounted at a rate of 3% annually.
ICER ¼ incremental cost-effectiveness ratio; QALY ¼ quality-adjusted life-year.
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DISCUSSION
In this non-industry-sponsored CEA evaluating sacubitril-valsartan combination therapy, we found The decision to describe an intervention as costeffective is based on WTP for the outcome of interest.
A commonly accepted WTP threshold in the United
States is $50,000 per QALY. It has been suggested that this value is too low in the United States and should therefore be thought of as a lower-bound estimate (31) . A more appropriate threshold may be $100,000 to $150,000 per QALY, or even higher (31, 32) .
However, WTP does not take into account disease prevalence and budget impact, which also influence decisions. The choice of WTP threshold is of particular interest with ARNI because our results found that sacubitril-valsartan was highly likely to be costeffective given a WTP of $100,000 per QALY or higher ($80% of simulations in PSA were cost-effective at this value) but not at a WTP of $50,000 per QALY. population, the increased price of ARNIs will likely place a significant cost burden on payers, particularly
Medicare. Decision makers must determine whether the extra benefit with sacubitril-valsartan observed in PARADIGM-HF is worth the additional costs. This is the first peer-reviewed study to examine the cost- 
